跳至主要内容
临床试验/2025-523965-97-00
2025-523965-97-00招募中2 期

The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients

Turku University Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年12月16日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
60
试验地点
1
主要终点
SUVmax, SUVmean and SUVpeak of the primary tumor, tumor recurrence, lymph node metastasis or distant metastasis

研究概览

简要总结

  1. To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the clinical assessment of patients with lymph node metastases in NSCLC
  2. To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessment of cancer related distant metastasis in patient level in patients with primary NSCLC
  3. To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessesment of cancer related local lymph metastasis and distant metastasis in patient level in patients with recurrent NSCL.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • Diagnosis: Histologically confirmed adenocarcinoma or squamous cell carcinoma. Study 1: No previous treatment (surgical, radiotherapy or medical treatment) for NSCLC. Study 2: Lobectomy or stereotactical radiotherapy or chemoradiotherapy for NSCLC. Clinical stage: Study 1: Stage I-III, Age: > 18 yo.

排除标准

  • Infections: Patient must not have an uncontrolled serious infection - no other malignancies - no known history of sarcoidosis - Study 2: under six months after radiotherapy - Patient is not able to understand purpose of study - Medical conditions prohibiting whole body PET-CT

结局指标

主要结局

SUVmax, SUVmean and SUVpeak of the primary tumor, tumor recurrence, lymph node metastasis or distant metastasis

SUVmax, SUVmean and SUVpeak of the primary tumor, tumor recurrence, lymph node metastasis or distant metastasis

次要结局

  • Histological confirmation of cancer in lesions with FAPI PET -imaging

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Jukka Kemppainen

Scientific

Turku University Hospital

研究点 (1)

Loading locations...

相似试验